Prof. Dr. med. Mark Schrader - Urologie, Berlin - Publikationen

1. Streicher W, Zengerling F, Laschak M, Weidemann W, Hopfner M, Schrader AJ, Jentzmik F, Schrader M, Cronauer MV. AR-Q640X, a model to study the effects of constitutively active C-terminally truncated AR variants in prostate cancer cells.World J Urol. 2012.

2. Jentzmik F, Schrader M, de Petriconi R, Hefty R, Doetterl J, Eickhoff A, Schrader AJ. [Radical cystectomy and ileal neobladder reconstruction in elderly female patients over 70 years old : Morbidity, functional and oncological long-term results].Urologe A. 2012;51:1419-23.

3. Rinnab L, Schrader AJ, Schrader M, Zengerling F. [Male sexuality in the elderly]. Urologe A. 2012;51:1399-413.

4. Steffens S, Kohler A, Rudolph R, Eggers H, Seidel C, Janssen M, Wegener G, Schrader M, Kuczyk MA, Schrader AJ.Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC cancer. 2012;12:399.

5. Steffens S, Janssen M, Roos FC, Becker F, Schumacher S, Seidel C, Wegener G, Thuroff JW, Hofmann R, Stockle M, Siemer S, Schrader M, Hartmann A, Kuczyk MA, Junker K, Schrader AJ. Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma - A multicentre study. Eur J Cancer. 2012.

6. Schrader AJ, Steffens S, Schnoeller TJ, Schrader M, Kuczyk MA. Neoadjuvant therapy of renal cell carcinoma: A novel treatment option in the era of targeted therapy? International journal of urology : official journal of the Japanese Urological Association. 2012.

7. Schnoeller T, Jentzmik F, Rinnab L, Cronauer MV, Damjanoski I, Zengerling F, Ghazal AA, Schrader M, Schrader AJ.Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer. World J Urol. 2012.

8. Rogenhofer S, Zengerling F, Schrader M, Muller SC. [Guidelines: reality and quality.]. Urologe A. 2012.

9. Rinckleb AE, Surowy HM, Luedeke M, Varga D, Schrader M, Hoegel J, Vogel W, Maier C. The prostate cancer risk locus at 10q11 is associated with DNA repair capacity. DNA repair. 2012.

10. Muller J, Schrader M, Schrader AJ, Hopfner M, Zengerling F. [Value of positron emission tomography in urological neoplasms : More form than substance?]. Urologe A. 2012.

11. Mueller J, Schrader AJ, Schnoeller T, Zengerling F, Damjanoski I, Al Ghazal A, Schrader M, Jentzmik F. The retrourethral transobturator sling suspension in the treatment of male urinary stress incontinence: results of a single institution experience. ISRN urology. 2012;2012:304205.

12. Luedeke M, Coinac I, Linnert CM, Bogdanova N, Rinckleb AE, Schrader M, Vogel W, Hoegel J, Meyer A, Dork T, Maier C. Prostate Cancer Risk Is not Altered by TP53AIP1 Germline Mutations in a German Case-Control Series. PLoS One. 2012;7:e34128.

13. Laschak M, Spindler KD, Schrader AJ, Hessenauer A, Streicher W, Schrader M, Cronauer MV. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells. BMC cancer. 2012;12:130.

14. Jentzmik F, Schrader AJ, de Petriconi R, Hefty R, Mueller J, Doetterl J, Eickhoff A, Schrader M. The ileal neobladder in female patients with bladder cancer: long-term clinical, functional, and oncological outcome. World J Urol. 2012.

15. Gloesenkamp C, Nitzsche B, Lim AR, Normant E, Vosburgh E, Schrader M, Ocker M, Scherubl H, Hopfner M. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors. Int J Oncol. 2012.

16. Erber B, Schrader M, Miller K, Schostak M, Baumunk D, Lingnau A, Schrader AJ, Jentzmik F. Morbidity and Quality of Life in Bladder Cancer Patients following Cystectomy and Urinary Diversion: A Single-Institution Comparison of Ileal Conduit versus Orthotopic Neobladder. ISRN urology. 2012;2012:342796.

17. Busch J, Erber B, Friedersdorff F, Hoffmann I, Magheli A, Kempkensteffen C, Weikert S, Miller K, Schrader M, Hinz S. Laparoscopic and open postchemotherapy retroperitoneal lymph node dissection in patients with advanced testicular cancer - a single center analysis. BMC urology. 2012;12:15.

18. Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gossele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Dohner H, Chiosis G, Glimm H, Frohling S, Scholl C. Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. J Exp Med. 2012.

19. Zengerling F, Schrader AJ, Schrader M, Jentzmik F. [Diagnostic Relevance of Choline-PET / CT in Patients with Prostate Cancer.]. Aktuelle Urol. 2011.

20. Wittig-Blaich SM, Kacprzyk LA, Eismann T, Bewerunge-Hudler M, Kruse P, Winkler E, Strauss WS, Hibst R, Steiner R, Schrader M, Mertens D, Sultmann H, Wittig R. Matrix-Dependent Regulation of AKT in Hepsin-Overexpressing PC3 Prostate Cancer Cells. Neoplasia. 2011;13:579-89.

21. Winter C, Pfister D, Busch J, Bingol C, Ranft U, Schrader M, Dieckmann KP, Heidenreich A, Albers P. Residual Tumor Size and IGCCCG Risk Classification Predict Additional Vascular Procedures in Patients with Germ Cell Tumors and Residual Tumor Resection: A Multicenter Analysis of the German Testicular Cancer Study Group. Eur Urol. 2011.

22. Waalkes S, Rott H, Herrmann TR, Wegener G, Kramer MW, Merseburger AS, Schrader M, Hofmann R, Kuczyk MA, Schrader AJ. Does male sex influence the prognosis of patients with renal cancer? Onkologie. 2011;34:24-8.

23. Waalkes S, Roos FC, Eggers H, Schumacher S, Janssen M, Wegener G, Thuroff JW, Hofmann R, Schrader M, Kuczyk MA, Schrader AJ. [Incidence and long-term prognosis of papillary renal cancer : Results of a retrospective multicenter study.]. Urologe A. 2011.

24. Waalkes S, Eggers H, Rustemeier J, Wegener G, Jentzmik F, Schrader M, Hofmann R, Kuczyk MA, Schrader AJ.[Overweight is an advantageous prognostic marker in patients with clear cell kidney cancer.]. Urologe A. 2011.

25. Waalkes S, Becker F, Schrader AJ, Janssen M, Wegener G, Merseburger AS, Schrader M, Hofmann R, Stockle M, Kuczyk MA. Is there a need to further subclassify pT2 renal cell cancers as implemented by the revised 7th TNM version? Eur Urol. 2011;59:258-63.

26. Stephan C, Siembetaen K, Cammann H, Friedersdorff F, Deger S, Schrader M, Miller K, Lein M, Jung K, Meyer HA.Between-Method Differences in Prostate-Specific Antigen Assays Affect Prostate Cancer Risk Prediction by Nomograms. Clin Chem. 2011.

27. Steffens S, von Klot C, Eggers H, Seidel C, Wegner G, Schrader M, Kuczyk MA, Schrader AJ. The role of diabetes mellitus in localized and metastatic renal cell carcinoma. Journal of Diabetes. 2011;1.

28. Steffens S, Grunwald V, Ringe KI, Seidel C, Eggers H, Schrader M, Wacker F, Kuczyk MA, Schrader AJ. Does Obesity Influence the Prognosis of Metastatic Renal Cell Carcinoma in Patients Treated with Vascular Endothelial Growth Factor-Targeted Therapy? Oncologist. 2011.

29. Sell K, Barth PJ, Moll R, Thomas MA, Zimmer N, Oplesch E, Gudo M, Schrader M, Hofmann R, Schrader AJ.Localization of FOXP3-positive cells in renal cell carcinoma. Tumour Biol. 2011.

30. Schutz SV, Schrader AJ, Zengerling F, Genze F, Cronauer MV, Schrader M. Inhibition of glycogen synthase kinase-3beta counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer. PLoS One. 2011;6:e25341.

31. Schnoller TJ, Jentzmik F, Al Ghazal A, Zengerling F, de Petriconi R, Hefty R, Rinnab L, Schrader M, Schrader AJ.[Renal masses in pregnancy : Diagnostics and therapeutic management.]. Urologe A. 2011.

32. Schnoeller TJ, de Petriconi R, Hefty R, Jentzmik F, Waalkes S, Zengerling F, Schrader M, Schrader AJ. Partial nephrectomy using porcine small intestinal submucosa. World J Surg Oncol. 2011;9:126.

33. Muller J, Schrader AJ, Jentzmik F, Schrader M. [Assessment of residual tumours after systemic treatment of metastatic seminoma: (1)F-2-fluoro-2-deoxy-D-glucose positron emission tomography - meta-analysis of diagnostic value].Urologe A. 2011;50:322-7.

34. Jentzmik F, Schrader AJ, Schrader M. Re: Beat Roth, Frederic D. Birkhauser, Pascal Zehnder, et al. Readaptation of the peritoneum following extended pelvic lymphadenectomy and cystectomy has a significant beneficial impact on early postoperative recovery and complications: results of a prospective randomized trial. Eur Urol 2011;59:204-10. Eur Urol. 2011;59:e17-8; author reply e9.

35. Jentzmik F, Krause H, Reichelt U, Schrader AJ, Schrader M, Baumunk D, Cash H, Miller K, Schostak M. GSTP1 CpG island hypermethylation for DNA-based detection of occult tumor cells in surgical margins after radical prostatectomy. World J Urol. 2011.

36. Jain G, Cronauer MV, Schrader M, Moller P, Marienfeld RB. NF-kappaB signaling in prostate cancer: A promising therapeutic target? World J Urol. 2011.

37. Gschwend JE, Albers P, Schrader M. [Certified prostate cancer centers and second opinion centers for testicular cancer : Successful models of uro-oncology cancer care]. Urologe A. 2011;50:921-7.

38. Schrader M, Weissbach L, Hartmann M, Krege S, Albers P, Miller K, Heidenreich A. Burden or relief: do second-opinion centers influence the quality of care delivered to patients with testicular germ cell cancer? Eur Urol. 2010;57:867-72.

39. Gakis G, Jentzmik F, Schrader M, Stenzl A, Sievert KD. [Benefits and risks of orthotopic neobladder reconstruction in female patients]. Aktuelle Urol. 2011;42:109-14.

40. Jentzmik F, Stephan C, Miller K, Schrader M, Erbersdobler A, Kristiansen G, Lein M, Jung K. Sarcosine in Urine after Digital Rectal Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours. Eur Urol. 2010.

41. Wenz F, Martin T, Bohmer D, Martens S, Sedlmayer F, Wirth M, Miller K, Heidenreich A, Schrader M, Hinkelbein W, Wiegel T. The German S3 Guideline Prostate Cancer : Aspects for the Radiation Oncologist. Strahlenther Onkol. 2010.

42. Waalkes S, Merseburger AS, Kramer MW, Herrmann TR, Wegener G, Rustemeier J, Hofmann R, Schrader M, Kuczyk MA, Schrader AJ. Obesity is associated with improved survival in patients with organ-confined clear-cell kidney cancer. Cancer Causes Control. 2010.

43. Waalkes S, Becker F, Schrader AJ, Janssen M, Wegener G, Merseburger AS, Schrader M, Hofmann R, Stockle M, Kuczyk MA. Is There a Need to Further Subclassify pT2 Renal Cell Cancers as Implemented by the Revised 7th TNM Version? Eur Urol. 2010.

44. Strenziok R, Hinz S, Wolf C, Conrad T, Krause H, Miller K, Schrader M. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry: serum protein profiling in seminoma patients. World J Urol. 2010;28:193-7.

45. Schrader M. [Germ cell cancer--an update]. Urologe A. 2010;49 Suppl 1:166-8.

46. Schaefer A, Jung M, Kristiansen G, Lein M, Schrader M, Miller K, Stephan C, Jung K. MicroRNAs and cancer: current state and future perspectives in urologic oncology. Urol Oncol. 2010;28:4-13.

47. Nitzsche B, Gloesenkamp C, Schrader M, Ocker M, Preissner R, Lein M, Zakrzewicz A, Hoffmann B, Hopfner M. Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours. Br J Cancer. 2010;103:18-28.

48. Muller J, Schrader AJ, Jentzmik F, Schrader M. [Assessment of residual tumours after systemic treatment of metastatic seminoma : (18)F-2-Fluoro-2-deoxy-D-glucose positron emission tomography - Meta-analysis of diagnostic value.]. Urologe A. 2010.

49. Jentzmik F, Schrader AJ, Schrader M. Reply to Yiping Zhu, Dingwei Ye's Letter to the Editor re: Beat Roth, Frederic D. Birkhauser, Pascal Zehnder, et al. Readaptation of the Peritoneum Following Extended Pelvic Lymphadenectomy and Cystectomy Has a Significant Beneficial Impact on Early Postoperative Recovery and Complications: Results of a Prospective Randomized Trial. Eur Urol 2011;59:204-10. Eur Urol. 2010.

50. Jentzmik F, Schostak M, Stephan C, Baumunk D, Lingnau A, Weikert S, Lein M, Miller K, Schrader M. Extraperitoneal radical cystectomy with extraperitonealization of the ileal neobladder: a comparison to the transperitoneal technique. World J Urol. 2010;28:457-63.

51. Hinz S, Magheli A, Weikert S, Schulze W, Krause H, Schrader M, Miller K, Kempkensteffen C. Deregulation of EZH2 expression in human spermatogenic disorders and testicular germ cell tumors. World J Urol. 2010;28:631-5.

52. Ecke TH, Bartel P, Hallmann S, Koch S, Ruttloff J, Cammann H, Lein M, Schrader M, Miller K, Stephan C. Outcome prediction for prostate cancer detection rate with artificial neural network (ANN) in daily routine. Urol Oncol. 2010.

53. Busch J, Rollig C, Weissbach L, Kempkensteffen C, Hinz S, Jahnke C, Schostak M, Lein M, Weikert S, Stephan C, Deger S, Ollenschlager G, Miller K, Schrader M. [What is most important is what comes across : Urological guidelines from the target group's point of view]. Urologe A. 2010;49:75-80.

54. Busch J, C. Röllig b,1, L. Weißbach c, C. Jahnke a, C. Kempkensteffen a, S. Hinz a, M. Schostak a,, C. Stephan a SWa, G. Ollenschläger b, K. Miller a, M. Schrader a. Use of national and international guidelines by German urologists—Results of a survey. European Journal of Integrative Medicine. 2010;2:129–33.

55. Thilo F, Baumunk D, Krause H, Schrader M, Miller K, Loddenkemper C, Zakrzewicz A, Krueger K, Zidek W, Tepel M. Transient receptor potential canonical type 3 channels and blood pressure in humans. J Hypertens. 2009.

56. Stephan C, Rittenhouse H, Cammann H, Lein M, Schrader M, Deger S, Miller K, Jung K. New markers and multivariate models for prostate cancer detection. Anticancer Res. 2009;29:2589-600.

57. Stephan C, Kopke T, Semjonow A, Lein M, Deger S, Schrader M, Miller K, Jung K. Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem? Clin Chem Lab Med. 2009;47:1325-31.

58. Stephan C, Kopke T, Semjonow A, Lein M, Deger S, Schrader M, Miller K, Jung K. Review: Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem? Clin Chem Lab Med. 2009.

59. Stephan C, Cammann H, Rittenhouse H, Lein M, Jentzmik F, Schrader M, Deger S, Miller K, Jung K. [New biomarkers and application of multivariate models for detection of prostate cancer]. Aktuelle Urol. 2009;40:221-30.

60. Stephan C, Cammann H, Deger S, Schrader M, Meyer HA, Miller K, Lein M, Jung K. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network. Urology. 2009;74:873-7.

61. Schrader M, Kempkensteffen C, Christoph F, Hinz S, Weikert S, Lein M, Krause H, Stephan C, Jung K, Hoepfner M, Albers P, Miller K, Schostak M. Germ cell tumors of the gonads: a selective review emphasizing problems in drug resistance and current therapy options. Oncology. 2009;76:77-84.

62. Schrader M, Hartmann M, Krege S, Heidenreich A, Miller K, Weissbach L. [Testicular germ cell cancer : Interdependence between guidelines and a second-opinion system.]. Urologe A. 2009.

63. Schaefer A, Jung M, Kristiansen G, Lein M, Schrader M, Miller K, Erbersdobler A, Stephan C, Jung K. [MicroRNA in uro-oncology : New hope for the diagnosis and treatment of tumors?]. Urologe A. 2009.

64. Lein M, Miller K, Wirth M, Weissbach L, May C, Schmidt K, Haus U, Schrader M, Jung K. Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. Prostate. 2009.

65. Kempkensteffen C, Hinz S, Johannsen M, Krause H, Magheli A, Christoph F, Kollermann J, Schrader M, Schostak M, Miller K, Weikert S. Expression of Mcl-1 Splicing Variants in Clear-Cell Renal Cancer and Their Correlation with Histopathological Parameters and Prognosis. Tumour Biol. 2009;30:73-9.

66. Jentzmik F, Schostak M, Stephan C, Baumunk D, Lingnau A, Weikert S, Lein M, Miller K, Schrader M. Extraperitoneal radical cystectomy with extraperitonealization of the ileal neobladder: a comparison to the transperitoneal technique. World J Urol. 2009.

67. Hinz S, Rais-Bahrami S, Weiske WH, Kempkensteffen C, Schrader M, Miller K, Magheli A. Prognostic value of intraoperative parameters observed during vasectomy reversal for predicting postoperative vas patency and fertility. World J Urol. 2009.

68. Stephan C, Kahrs AM, Cammann H, Lein M, Schrader M, Deger S, Miller K, Jung K. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate. 2008.

69. Stephan C, Cammann H, Schrader M, Deger S, Lein M, Jung K. Reply. BJU Int. 2008;102:902.

70. Schreiter N, Jagota A, Popken G, Akhavuz O, Nitzke T, Duffelmeyer M, Fischer T, Schostak M, Miller K, Schrader M. [Germ cell tumors - documentation of diagnosis and therapy by means of a web-based modular database system]. Aktuelle Urol. 2008;39:442-7.

71. Schostak M, Miller K, Schrader M. Radical prostatectomy in the 21st century - the gold standard for localized and locally advanced prostate cancer. Front Radiat Ther Oncol. 2008;41:7-14.

72. Schostak M, Miller K, Schrader M. Hormone therapy for prostate cancer - immediate initiation. Front Radiat Ther Oncol. 2008;41:49-57.

73. Ramankulov A, Lein M, Johannsen M, Schrader M, Miller K, Loening SA, Jung K. Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. Cancer Lett. 2008.

74. Ramankulov A, Lein M, Johannsen M, Schrader M, Miller K, Jung K. Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas. Cancer Sci. 2008;99:1188-94.

75. Miller K, Lein M, Schostak M, Schrader M. [Adjuvant and neoadjuvant drug therapy for prostate cancer.]. Urologe A. 2008.

76. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Stahl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fossa SD, del Muro XG, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Galvis OL, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Paz-Ares L, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol. 2008;53:497-513.

77. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Stahl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fossa SD, del Muro XG, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Galvis OL, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Ares LP, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol. 2008;53:478-96.

78. Kempkensteffen C, Hinz S, Krause H, Jager T, Kollermann J, Weikert S, Christoph F, Schostak M, Miller K, Schrader M. Expression of Splicing Variants of the Inhibitor of Apoptosis Livin in Testicular Germ Cell Tumors. Tumour Biol. 2008;29:76-82.

79. Kempkensteffen C, Hinz S, Jager T, Weikert S, Krause H, Schostak M, Christoph F, Strenziok R, Miller K, Schrader M. [Expression levels of the IAP antagonists XAF1, Smac/DIABLO and HtrA2 in testicular germ cell tumours]. Aktuelle Urol. 2008;39:436-41.

80. Jung K, Ramankulov A, Schrader M, Miller K, Lein M. Circulating matrix metalloproteinase-7: an early or metastatic marker for renal cell carcinoma? Clin Chem. 2008;54:1927-9.

81. Hinz S, Schrader M, Kempkensteffen C, Bares R, Brenner W, Krege S, Franzius C, Kliesch S, Heicappel R, Miller K, de Wit M. The Role of Positron Emission Tomography in the Evaluation of Residual Masses After Chemotherapy for Advanced Stage Seminoma. J Urol. 2008.

82. Hinz S, Rais-Bahrami S, Kempkensteffen C, Weiske WH, Schrader M, Magheli A. Fertility Rates following Vasectomy Reversal: Importance of Age of the Female Partner. Urol Int. 2008;81:416-20.

83. Hinz S, Kempkensteffen C, Christoph F, Krause H, Schrader M, Schostak M, Miller K, Weikert S. Expression Parameters of the Polycomb Group Proteins BMI1, SUZ12, RING1 and CBX7 in Urothelial Carcinoma of the Bladder and Their Prognostic Relevance. Tumour Biol. 2008;29:323-9.

84. Ebbing J, Christoph F, Kempkensteffen C, Weikert S, Schostak M, Hinz S, Lein M, Miller K, Schrader M. [Testicular cancer - explanatory models for high cisplatin chemosensibility and new therapeutic options]. Aktuelle Urol. 2008;39:429-35.

85. Christoph F, Hinz S, Weikert S, Kempkensteffen C, Schostak M, Miller K, Schrader M. Comparative promoter methylation analysis of p53 target genes in urogenital cancers. Urol Int. 2008;80:398-404.

86. Schrader M, Miller K, Schostak M. Re: Christian Barre. Open Radical Retropubic Prostatectomy. Eur Urol 2007;52:71-80. Eur Urol. 2007.

87. Schostak M, Krause H, Miller K, Schrader M, Kempkensteffen C, Kollermann J. Does the molecular staging in pelvic lymph nodes improve the detection of relevant prostate cancer metastases? An assessment after 6 years. BJU Int. 2007.

88. Schostak M, Braun C, Krause H, Miller K, Kempkensteffen C, Hinz S, Strenziok R, Blana A, Schrader M. [New Polymorphisms in the PSA Promoter in Patients with Prostate Carcinoma.]. Aktuelle Urol. 2007;38:465-71.

89. Li Zhang L, Yan Liu D, Qun Ma L, Dan Luo Z, Bing Cao T, Zhong J, Cheng Yan Z, Juan Wang L, Gang Zhao Z, Jun Zhu S, Schrader M, Thilo F, Ming Zhu Z, Tepel M. Activation of Transient Receptor Potential Vanilloid Type-1 Channel Prevents Adipogenesis and Obesity. Circ Res. 2007.

90. Krause H, Schrader M, Miller K. Molekulare translationale Forschung – eine Gegenüberstellung internationaler Entwicklungen und eigener Forschungsansätze. Urologe A. 2007.

91. Kempkensteffen C, Jager T, Bub J, Weikert S, Hinz S, Christoph F, Krause H, Schostak M, Miller K, Schrader M. The equilibrium of XIAP and Smac/DIABLO expression is gradually deranged during the development and progression of testicular germ cell tumours. Int J Androl. 2007.

92. Kempkensteffen C, Hinz S, Schrader M, Christoph F, Magheli A, Krause H, Schostak M, Miller K, Weikert S. Gene expression and promoter methylation of the XIAP-associated Factor 1 in renal cell carcinomas: Correlations with pathology and outcome. Cancer Lett. 2007.

93. Kempkensteffen C, Hinz S, Christoph F, Krause H, Magheli A, Schrader M, Schostak M, Miller K, Weikert S. Expression levels of the mitochondrial IAP antagonists Smac/DIABLO and Omi/HtrA2 in clear-cell renal cell carcinomas and their prognostic value. J Cancer Res Clin Oncol. 2007.

94. Kempkensteffen C, Hinz S, Christoph F, Krause H, Koellermann J, Magheli A, Schrader M, Schostak M, Miller K, Weikert S. Expression of the Apoptosis Inhibitor Livin in Renal Cell Carcinomas: Correlations with Pathology and Outcome. Tumour Biol. 2007;28:132-8.

95. Hinz S, Kempkensteffen C, Weikert S, Schostak M, Schrader M, Miller K, Christoph F. EZH2 Polycomb Transcriptional Repressor Expression Correlates with Methylation of the APAF-1 Gene in Superficial Transitional Cell Carcinoma of the Bladder. Tumour Biol. 2007;28:151-7.

96. Hinz S, Kempkensteffen C, Christoph F, Hoffmann M, Krause H, Schrader M, Schostak M, Miller K, Weikert S. Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder.J Cancer Res Clin Oncol. 2007.

97. Dossow V, Fritsche L, Geringhoff-Seckler J, Guckelberger O, Kissner L, Möckel M, Tegethoff K, Schrader M. Oberarzt-Einstufung - Kriterien erstmals klar geregelt. Deutsches Ärzteblatt. 2007;17:1007-9.

98. Christoph F, Moschkowitsch A, Kempkensteffen C, Schostak M, Miller K, Schrader M. Long-term efficacy of tolterodine and patient compliance in pediatric patients with neurogenic detrusor overactivity. Urol Int. 2007;79:55-9.

99. Christoph F, Hinz S, Kempkensteffen C, Schostak M, Schrader M, Miller K. mRNA Expression Profiles of Methylated APAF-1 and DAPK-1 Tumor Suppressor Genes Uncover Clear Cell Renal Cell Carcinomas With Aggressive Phenotype. J Urol. 2007.

100. Weikert S, Christoph F, Schulze W, Krause H, Kempkensteffen C, Schostak M, Miller K, Schrader M. Testicular expression of survivin and human telomerase reverse transcriptase (hTERT) associated with spermatogenic function in infertile patients. Asian J Androl. 2006;8:95-100.

101. Schrader M, Miller K. Re: Udo Nagele, Markus Kuczyk, Aristotelis G. Anastasiadis, Karl-Dietrich Sievert, Jorg Seibold, Arnulf Stenzl. Radical Cystectomy and Orthotopic Bladder Replacement in Females, Eur Urol 2006;50:249-257. Eur Urol. 2006.

102. Schrader M, Hartmann M, Krege S, Miller K, Weissbach L. ["Second opinion centers" Approach for improving the quality of treatment for testicular tumors.]. Urologe A. 2006.

103. Schostak M, Miller K, Krause H, Schrader M, Kempkensteffen C, Kollermann J. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions. Cancer Detect Prev. 2006.

104. Schostak M, Krause H, Miller K, Schrader M, Weikert S, Christoph F, Kempkensteffen C, Kollermann J. Quantitative real-time RT-PCR of CD24 mRNA in the detection of prostate cancer. BMC urology. 2006;6:7.

105. Kollermann J, Kempkensteffen C, Helpap B, Schrader M, Krause H, Muller M, Miller K, Schostak M. Impact of hormonal therapy on the detection of promoter hypermethylation of the detoxifying glutathione-S-transferase P1 gene (GSTP1) in prostate cancer. BMC urology. 2006;6:15.

106. Kempkensteffen C, Hinz S, Christoph F, Weikert S, Schrader M, Schostak M. [Rectal perforation as a late complication of ProACT implantation.]. Urologe A. 2006.

107. Kempkensteffen C, Hinz S, Christoph F, Kollermann J, Krause H, Schrader M, Schostak M, Miller K, Weikert S. Expression parameters of the inhibitors of apoptosis cIAP1 and cIAP2 in renal cell carcinomas and their prognostic relevance. Int J Cancer. 2006.

108. Kempkensteffen C, Christoph F, Weikert S, Krause H, Kollermann J, Schostak M, Miller K, Schrader M. Epigenetic silencing of the putative tumor suppressor gene testisin in testicular germ cell tumors. J Cancer Res Clin Oncol. 2006.

109. Christoph F, Weikert S, Wolff I, Schostak M, Tabiti K, Muller M, Miller K, Schrader M. Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder. Cancer Lett. 2006.

110. Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Miller K, Schrader M. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder. Int J Cancer. 2006.

111. Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Kollermann J, Miller K, Schrader M. Promoter Hypermethylation Profile of Kidney Cancer with New Proapoptotic p53 Target Genes and Clinical Implications. Clin Cancer Res. 2006;12:5040-6.

112. Christoph F, Kempkensteffen C, Weikert S, Krause H, Schostak M, Miller K, Schrader M. Frequent epigenetic inactivation of p53 target genes in seminomatous and nonseminomatous germ cell tumors. Cancer Lett. 2006.

113. Christoph F, Kempkensteffen C, Weikert S, Kollermann J, Krause H, Miller K, Schostak M, Schrader M. Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. Br J Cancer. 2006.

114. Christoph F, Hinz S, Kempkensteffen C, Weikert S, Krause H, Schostak M, Schrader M, Miller K. A gene expression profile of tumor suppressor genes commonly methylated in bladder cancer. J Cancer Res Clin Oncol. 2006.

115. Weikert S, Schrader M, Muller M, Schulze W, Krause H, Miller K. Expression levels of the inhibitor of apoptosis survivin in testes of patients with normal spermatogenesis and spermatogenic failure. Fertil Steril. 2005;83 Suppl 4:1100-5.

116. Weikert S, Schrader M, Krause H, Schulze W, Muller M, Miller K. The inhibitor of apoptosis (IAP) survivin is expressed in human testicular germ cell tumors and normal testes. Cancer Lett. 2005;223:331-7.

117. Weikert S, Schrader M, Christoph F, Schulze W, Krause H, Muller M, Miller K. Quantification of survivin mRNA in testes of infertile patients and in testicular germ cell tumours: high levels of expression associated with normal spermatogenesis. Int J Androl. 2005;28:224-9.

118. Weikert S, Krause H, Wolff I, Christoph F, Schrader M, Emrich T, Miller K, Muller M. Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer. Int J Cancer. 2005.

119. Weikert S, Christoph F, Schrader M, Krause H, Miller K, Muller M. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer. 2005.

120. Weikert S, Christoph F, Muller M, Schostak M, Miller K, Schrader M. Acucise endopyelotomy: A technique with limited ef fi cacy for primary ureteropelvic junction obstruction in adults. International journal of urology : official journal of the Japanese Urological Association. 2005;12:864-8.

121. Weikert S, Christoph F, Kollermann J, Muller M, Schrader M, Miller K, Krause H. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med. 2005;16:349-53.

122. Wang W, Ji P, Steffen B, Metzger R, Schneider PM, Halfter H, Schrader M, Berdel WE, Serve H, Muller-Tidow C. Alterations of lymphoid enhancer factor-1 isoform expression in solid tumors and acute leukemias. Acta Biochim Biophys Sin (Shanghai). 2005;37:173-80.

123. Schrader M, Weissbach L, Miller K. Paper tigers-Do clinical guidelines improve health care quality in patients with testicular germ cell tumors in Germany? Health Policy. 2005.

124. Schrader M, Krause H, Weikert S, Straub B, Schostak M, Christoph F, Miller K. Kinetic fluorescence rt-pcr is highly sensitive for detection of germ-cell-tumor-specific transcripts in peripheral blood. Int J Mol Med. 2005;16:143-7.

125. Schostak M, Matischak K, Schafer M, Muller M, Schrader M, Christoph F, Miller K. [New concept minimizes bleeding in radical retropubic prostatectomy.]. Urologe A. 2005.

126.